


PF-03654746 Tosylate

Cat. No.:	HY-11044
CAS No.:	1039399-17-1
Molecular Formula:	C ₂₅ H ₃₂ F ₂ N ₂ O ₄ S
Molecular Weight:	494.59
Target:	Histamine Receptor
Pathway:	GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

H₂O : ≥ 8.4 mg/mL (16.98 mM)
* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM	2.0219 mL	10.1094 mL	20.2188 mL
	5 mM	0.4044 mL	2.0219 mL	4.0438 mL	
	10 mM	0.2022 mL	1.0109 mL	2.0219 mL	

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

PF-03654746 Tosylate is a potent and selective histamine H3 receptor antagonist with high brain penetration. PF-03654746 Tosylate reduces allergen-induced nasal symptoms^[1]. PF-03654746 Tosylate has potential for treatment of human cognitive disorders, improves cognitive efficacy and disease-modifying effects in Alzheimer's disease (AD)^[2].

IC₅₀ & Target

H3 receptor^[1]

REFERENCES

[1]. Wager TT, et. al. Discovery of two clinical histamine H(3) receptor antagonists: trans-N-ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidinylmethyl)phenyl]cyclobutanecarboxamide (PF-03654746) and trans-3-fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]-N-(2-methylpropyl)cyclobutanecarboxamide (PF-03654764). J Med Chem. 2011 Nov 10;54(21):7602-20.

[2]. Stokes JR, et al. The effects of an H3 receptor antagonist (PF-03654746) with fexofenadine on reducing allergic rhinitis symptoms. J Allergy Clin Immunol. 2012 Feb;129(2):409-12, 412.e1-2.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA